The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! About 344,008 shares traded hands. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 3.82% since March 10, 2016 and is downtrending. It has underperformed by 11.34% the S&P500.
The move comes after 5 months positive chart setup for the $829.78M company. It was reported on Oct, 13 by Barchart.com. We have $35.38 PT which if reached, will make NASDAQ:AMAG worth $373.40M more.
Analysts await AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings on November, 1. They expect $0.34 earnings per share, up 154.84% or $0.96 from last year’s $-0.62 per share. AMAG’s profit will be $11.56 million for 17.94 P/E if the $0.34 EPS becomes a reality. After $-0.02 actual earnings per share reported by AMAG Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -1,800.00% EPS growth.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage
Out of 5 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. AMAG Pharmaceuticals has been the topic of 15 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Raymond James initiated the shares of AMAG in a report on Tuesday, September 1 with “Outperform” rating. The firm earned “Outperform” rating on Wednesday, May 4 by Leerink Swann. The rating was maintained by Jefferies on Thursday, August 11 with “Buy”. Raymond James downgraded AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Wednesday, May 4 to “Market Perform” rating. Deutsche Bank reinitiated it with “Hold” rating and $71.0 target price in Thursday, September 3 report. The firm earned “Hold” rating on Wednesday, November 4 by Deutsche Bank. On Wednesday, August 19 the stock rating was downgraded by Zacks to “Strong-Buy”. As per Tuesday, August 18, the company rating was initiated by Jefferies. Deutsche Bank maintained the shares of AMAG in a report on Thursday, November 19 with “Hold” rating. Barclays Capital initiated the shares of AMAG in a report on Thursday, January 21 with “Equal-Weight” rating.
According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.CombidexÂ®, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.”
Insitutional Activity: The institutional sentiment decreased to 0.83 in 2016 Q2. Its down 0.79, from 1.62 in 2016Q1. The ratio is negative, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Teacher Retirement Of Texas, a Texas-based fund reported 4,864 shares. Moreover, Amer Gp has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 25,902 shares. Alps Advsr Inc holds 65,956 shares or 0.01% of its portfolio. Sg Americas Secs Ltd owns 9,700 shares or 0% of their US portfolio. State Of Tennessee Treasury Department last reported 26,600 shares in the company. Dekabank Deutsche Girozentrale accumulated 18,650 shares or 0.01% of the stock. Loomis Sayles Communication Limited Partnership, a Massachusetts-based fund reported 190 shares. Legal & General Public Ltd Company has 0% invested in the company for 9,492 shares. Royal Bank & Trust Of Canada holds 0.01% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 620,453 shares. Swiss Savings Bank has 56,157 shares for 0% of their US portfolio. Endurant Cap Mgmt Ltd Partnership holds 0.58% or 72,380 shares in its portfolio. Moreover, Nj State Employees Deferred Compensation Plan has 0.05% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 10,000 shares. Comerica State Bank has 34,700 shares for 0.01% of their US portfolio. Blackrock Institutional Tru Na accumulated 903,089 shares or 0% of the stock. Envestnet Asset Mgmt holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 2,924 shares.
More recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: Fool.com which released: “Why AMAG Pharmaceuticals, Inc. Is Tanking Today” on August 10, 2016. Also Fool.com published the news titled: “Why AMAG Pharmaceuticals, Inc. Plunged 19.2% in May” on June 12, 2016. Investingnews.com‘s news article titled: “AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next …” with publication date: October 13, 2016 was also an interesting one.
AMAG Company Profile
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.